EGFR and cancer: We previously developed a bispecific RIT targeting the overexpressed EGFR and EGFRvIII variant on cancer cells [15], designated as DT390-HuBiscFv806 (hDT806), by fusing two humanized single-chain variable fragments (scFv) derived from monoclonal antibody mAb806 to the truncated form of DT.